Please login to the form below
renal cell carcinoma
This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.
A look ahead to key trial readouts at ESMO
In immuno-oncology, this year’s offering includes a first showing for data in first-line advanced renal cell carcinoma for Merck KGaA/Pfizer’s Bavencio (avelumab) in the JAVELIN Renal ... Merck &Co/MSD – already dominating non-small cell lung
Latest news
-
NICE clears Ipsen’s Cabometyx in first-line kidney cancer
The UK’s cost-effectiveness watchdog NICE has recommended first-line use of Ipsen’s Cabometyx for treatment-naïve patients with advanced renal cell carcinoma (RCC), the most common form of ... Matthew Hickling, medical director of Ipsen UK &Ireland,
-
CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer
The committee said that while improvements in survival were seen in previously-untreated renal cell carcinoma patients given the combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) ... in combination with chemotherapy,
-
Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on kidney cancer drug
EUSA’s Fotivda approved for NHS use in Scotland. Specialist pharma company EUSA Pharma has welcomed the Scottish Medicines Consortium approval of its renal cell carcinoma treatment Fotivda (tivozanib). ... The SMC has approved its use on the NHS as a
-
BMS presses go on Nektar combo pivotal trials, despite data debate
The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and
-
Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?
EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
More from news
Approximately 5 fully matching, plus 136 partially matching documents found.
Latest Intelligence
-
Accelerating innovation
Although marketed as the orphan drug Cometriq for thyroid neoplasms, it’s as Cabometyx in renal cell carcinoma (RCC) where the firm views real potential.
-
Charting a course for expansion
Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease
-
Deal Watch March 2016
Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
-
Deal Watch December 2015
510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
-
Pharma deals during April 2014
Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). ... This was largely driven by the phase 2 autologous
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
-
CytomX appoints Rachel Humphrey chief medical officer
Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
Former Bayer oncology head Robert Rosen joins AP Pharma's board. While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma? ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
-
A stumble, but not a fall – what’s next for Opdivo?
and renal cell carcinoma (kidney cancer). ... Back then, the UK’ s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Director - Digital
-
Great salary and benefits
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Account Director – Global Healthcare PR
-
Salary TBC
- Director Healthcare PR Communications
-
Salary TBC
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Account Manager, Healthcare Advertising
-
Salary TBC
-
Associate Medical Director
-
Salary TBC
-
Scientific Director
-
Highly Competitive Salary &Benefits
-
Scientific Team Lead
-
Competitive Salary
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Account Director
-
Negotiable
Subscribe to our email news alerts
PMHub
Synergy Vision
Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...
Latest intelligence
- Tackling a formidable foe
- Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
- Cancer care – the power of new technologies
- With patient numbers set to soar, how can we make a difference?...
- Redefining communications excellence
- How to be heard in today’s multichannel, multistakeholder, multimedia world...
Quick links
Infographics
